Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi

EXPLORER-HCM Patient Screening Closes Ahead of Schedule – Initial Results Now Anticipated in the Second Quarter of 2020 Royalty Purchase Creates Additional Economic Value for MyoKardia’s Emerging HCM...
June 24, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive...
June 18, 2019 16:05 ET | Source: MyoKardia, Inc.

MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
May 28, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece

First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable...
May 09, 2019 16:05 ET | Source: MyoKardia, Inc.

MyoKardia Reports First Quarter 2019 Financial Results

Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 ...
May 08, 2019 16:10 ET | Source: MyoKardia, Inc.

MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 07, 2019 16:10 ET | Source: MyoKardia, Inc.

MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees

SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular...
May 02, 2019 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
April 30, 2019 08:30 ET | Source: MyoKardia, Inc.

Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine

Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with...
March 26, 2019 18:45 ET | Source: MyoKardia, Inc.

MyoKardia Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right